Search Results - "Touam, F."

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen by Palich, Romain, Allavena, Clotilde, Peytavin, Gilles, Soulie, Cathia, Tubiana, Roland, Weiss, Laurence, Montoya Ferrer, Ana, Duvivier, Claudine, Bouchaud, Olivier, Bottero, Julie, Durand, Aurore, Lê, Minh-Patrick, Marcelin, Anne-Geneviève, Dudoit, Yasmine, Assoumou, Lambert, Katlama, Christine

“…Abstract Background Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected…”
Get full text

Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers by Goupil de Bouillé, Jeanne, Vigouroux, Corinne, Plessis, Lorraine, Ghislain, Mathilde, Teglas, Jean-Paul, Boufassa, Faroudy, Goujard, Cécile, Vignes, Dorothée, Bouchaud, Olivier, Salmon, Dominique, Meyer, Laurence, Abgrall, Sophie

“…Abstract Background We investigated the association between socioclinical, inflammatory, and metabolic markers and weight gain in people with human…”
Get full text

HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort) by Santos, Melina Erica, Protopopescu, Camelia, Sogni, Philippe, Yaya, Issifou, Piroth, Lionel, Bailly, François, Marcellin, Fabienne, Esterle, Laure, Wittkop, Linda, Rosenthal, Eric, Morlat, Philippe, Roux, Perrine, de Araujo, Wildo Navegantes, Salmon-Ceron, Dominique, Carrieri, Maria Patrizia

“…Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance…”
Get full text

Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH) by Marcellin, Fabienne, Abgrall, Sophie, Roustant, F, Platterier, P, Kmiec, I, Parlier, S, Anriamiandrisoa, S, Pomes, C, Mole, M, Mebarki, M, Ousidhoum, Y, Braik, O, Bayoud, R, Gatey, C, Ben Rayana, R, Lions, C, Zelie, J, Ogoudjobi, S, Thoirain‐Galvan, V, Gilbert, C, Ramier, C, Izopet, J, Valantin, Chas, J, Duvivier, C, Morlat, P, Autran, B, Solas, C, Fontaine, H, Piroth, L, Peytavin, G, Tremeaux, P, Cacoub, P, Charlotte, F, Marchou, B, Selves, J, Larroquette, F, Rio, V, De Monte, A, Giordanengo, V, Partouche, C, Baazia, Y, Garipuy, D, Nicot, F, Adle‐Biassette, H, Alexandre, G, Molina, J.M, Bertheau, P, Quertainmont, Y, Teicher, E, Rouzaud, C, Castet‐Lafarie, S, Cazanave, C, Dupon, M, Dutronc, H, Dauchy, F, Desclaux, A, Bonnet, F, Bernard, N, Martell, C, Vandenhende, M, Malvy, D, Pistone, T, Méchain, M, Duffau, P, Faure, I, Caldato, S, Bellecave, P, Pellegrin, J.L, Bioulac‐Sage, P, Reigadas, S, Majerholc, C, Polo Devoto, J, Kansau, I, Pignon, C, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Boutoille, D, Rodallec, A, Le Guen, L, Peyramond, D, Chidiac, C, Ferry, T, Zoulim, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Koffi, J, Zoulim, F, Bailly, F, Maynard, M, Scholtes, C, Chavanet, P, Duong Van Huyen, M, Galim, S, Batard, M.L, Bernard‐Henry, C, de Mautort, E

Get full text

Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH) by Vilotitch, A., Esterle, L., Spire, B., Rey, D., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bouchaud, O, Goujard, C, Lacombe, K, Dominguez, S, Autran, B, Roque, A.M., Boué, F, Aumaître, H, Salmon, D, Katlama, C, Stitou, H, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Pialoux, G, Bendjaballah, F, Le Pendeven, C, Marchou, B, Selves, J, Uzan, M, Ferro‐Collados, M.J, Gervais, A, Adle‐Biassette, H, Molina, J.M, Duclos, J, Palmer, P, Girard, P.M, Viala, C, Goujard, C, Pallier, C, Lortholary, O, Duvivier, C, Mélard, A, Neau, D, Cazanave, C, Dupon, M, Reigadas, S, Lacoste, D, Roger‐Schmeltz, J, Carmen Pertusa, M, Vandenhende, M, Caldato, S, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Majerholc, C, Boué, F, Kansau, I, Chambrin, V, Pignon, C, Fior, R, Martinez, V, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Raffi, F, Ader, F, Biron, F, Boibieux, A, Koffi, J, Lack, P, Maynard, M, Amiri, M, Piroth, L, Chavanet, P, Waldner‐Combernoux, A, Croisier‐Bertin, D, Rouger, C, Beniken, D, Ritleng, A.‐S, Payssan, V, Breau, S, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Chesnel, C, Maradan, G, Kurkdji, P, Kmiec, I, Pietri, M.P, Guet, P, Mebarki, M, Delaune, J, Gillet, S, Jacquet, A, Protopopescu, C, Rosellini, S

“…Summary Liver steatosis is common in human immunodeficiency virus (HIV)‐hepatitis C virus (HCV)‐co‐infected patients. Some recent studies have found that…”
Get full text

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial by Pressiat, Claire, Hirt, Déborah, Treluyer, Jean-Marc, Zheng, Yi, Morlat, Philippe, Naqvi, Alice, Tran, Laurent, Viard, Jean-Paul, Avettand-Fenoel, Véronique, Rouzioux, Christine, Meyer, Laurence, Cheret, Antoine

“…The OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc)…”
Get full text

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial) by Soulié, Cathia, Assoumou, Lambert, Darty, Mélanie, Rodriguez, Christophe, Donati, Flora, Sayon, Sophie, Peytavin, Gilles, Valantin, Marc-Antoine, Caby, Fabienne, Schneider, Luminita, Canestri, Ana, Costagliola, Dominique, Katlama, Christine, Calvez, Vincent, Marcelin, Anne-Geneviève

“…ROCnRAL ANRS-157 was a single-arm study designed to evaluate a switch to a maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day) regimen in…”
Get full text

Characteristics and consequences of medical care interruptions in HIV-infected patients in France by CUZIN, L., DELLAMONICA, P., YAZDANPANAH, Y., BOUCHEZ, S., REY, D., HOEN, B., CABIÉ, A.

“…To describe the consequences of medical care interruptions (MCIs) we selected patients with at least two medical encounters between January 2006 and June 2013…”
Get full text

No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France by Cuzin, L, Yazdanpanah, Y, Huleux, T, Cotte, L, Pugliese, P, Allavena, C, Reynes, J, Poizot‐Martin, I, Zaegel‐Faucher, O, Obry‐Roguet, V, Soavi, MJ, Luquet‐Besson, I, Carta‐Padovani, M, Bertone, H, Galie, S, Galinier, A, Martinet, P, Ritleng, AS, Ivanova, A, Alvarez, M, Debard, A, Delobel, P, Martin‐Blondel, G, Porte, L, Mularczyk, M, Garipuy, D, Marcel, M, Puntis, E, Ceppi, C, Cua, E, Dellamonica, P, Dunais, B, Durant, J, Etienne, C, Ferrando, S, Risso, K, Mondain, V, Perbost, I, Wehrlen‐Pugliese, S, Rosenthal, E, Roger, PM, Billaud, E, Bonnet, B, Bouchez, S, Boutoille, D, Brunet‐Cartier, C, Jovelin, T, Hue, H, Rodallec, A, Vivrel, F, Biron, C, Cheret, A, Choisy, P, Landman, R, Duvivier, C, Agher, R, Lortholary, Rouzioux, C, Cessot, G, Touam, F, Usubillaga, R, Cabié, A, Abel, S, Pierre‐François, S, Ouka, M, Martial, J, Fischer, P, Partisani, M, Cheneau, C, Batard, ML, Bernard‐Henry, C, e Mautort, E, Drobacheff‐Thiébaut, C, Faucher, JF, Hustache‐Mathieu, L, Hoen, B, Jacomet, C, Lesens, O, Mrozek, N, Aumeran, C, Baud, O, Beytout, J, Coban, D, Casanova, S, Rouger, C, Berger, JL, N'Guyen, Y, Kmiec, I, Hentzien, M, Peyramond, D, Ader, F, Biron, F, Boibieux, A, Perpoint, T, Degroodt, S, Atoui, N, Casanova, ML, Le Moing, V, Meftah, N, Psomas, C

“…Objectives The aim of the study was to determine whether there is a relationship between social deprivation and time of HIV diagnosis in France. Methods…”
Get full text

Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study by Lê, Minh Patrick, Soulié, Cathia, Assoumou, Lambert, Valantin, Marc-Antoine, Duvivier, Claudine, Chas, Julie, Ponscarme, Diane, Marcelin, Anne-Geneviève, Calvez, Vincent, Katlama, Christine, Peytavin, Gilles

Get full text

An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy by Pugliese, P, Delpierre, C, Cuzin, L, Poizot‐Martin, I, Rey, D, Saune, K, Cottalorda, J, Bettinger, D, Delaugerre, C, Hoen, B

“…Objectives The aim of the study was to assess whether patients with undetectable viraemia [a negative polymerase chain reaction result (PCRneg)] and those with…”
Get full text

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study by Landman, Roland, Capitant, Catherine, Descamps, Diane, Chazallon, Corine, Peytavin, Gilles, Katlama, Christine, Pialoux, Gilles, Bentata, Michelle, Brun-Vézinet, Francoise, Aboulker, Jean-Pierre, Yéni, Patrick

“…Objectives We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing…”
Get full text

Évolution des marqueurs rénaux sous dolutégravir ou l’association emtricitabine/ténofovir/elvitégravir/cobicistat et corrélation avec les concentrations plasmatiques d’antirétroviraux by Lourenco, J., Peytavin, G., Avettand, V., Rouzaud, C., Lanternier, F., Charlier, C., Touam, F., Louisin, C., Lortholary, O., Duvivier, C.

“…Le dolutégravir (DTG) et le cobicistat (Cobi) associé à l’elvitégravir (EVG) sont connus pour augmenter les taux de créatinine en bloquant les transporteurs…”
Get full text